The age- and sex-matched multivariate analysis were also conducted, which showed that SGLT2 inhibitor therapy (HR: 0.48, 95% CI: 0.33–0.7; p < 0.001) and HDL-C (HR: 0.61, 95% CI: 0.51–0.74, p < 0.001) significantly reduced the incidence of stroke in our cohort (Table 4). The gene discussed is SLC5A2; the disease is Stroke.